Fuxiang Co., Ltd.: Wholly-owned subsidiary receives approval notice for its listing application of chemical raw material drugs

Fuxiang Co., Ltd. announced that its wholly-owned subsidiary, Jiangxi Xiangtai Life Science Co., Ltd., has recently received the “Approval Notice for the Marketing Authorization of Torasemide as a Chemical Active Pharmaceutical Ingredient” issued and approved by the National Medical Products Administration. Torasemide is a highly effective diuretic, mainly indicated for patients with edema caused by congestive heart failure, cirrhotic ascites, and kidney diseases. According to data from Mi Nei Network, in 2024, the sales amount of Torasemide in domestic urban and county-level public hospitals, urban and online pharmacies, urban community hospitals, and township health centers was approximately RMB 407 million.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned